^
Association details:
| Biomarker: | FGFR1 amplification |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Excerpt:
FGFR1 amplification has recently been detected in squamous cell lung cancer and in the lung cancer cell lines H1581, H520, and DMS-114 (4)...Ponatinib inhibited growth of H1581, H520, and DMS-114 cells with GI50 values of 32, 155, and 108 nmol/L, respectively (Fig. 5C), but had minimal effects on EGFR-mutant HCC827 lung cancer cells that lack constitutive FGFR phosphorylation (GI50 = 611 nmol/L; Fig. 5C; ref. 4).
DOI:
10.1158/1535-7163.MCT-11-0450
